Cardima Revelation Tx Trial Results Show 45% Cure Rate For AF Episodes
This article was originally published in The Gray Sheet
Executive Summary
Cardima is hoping that clinical data showing 85% of patients had a reduction in their AF episodes of greater than or equal to 50% after being treated with its Revelation Tx system will prompt FDA's Circulatory System Devices Panel to recommend approval